Compare NTRS & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTRS | RMD |
|---|---|---|
| Founded | 1889 | 1989 |
| Country | United States | United States |
| Employees | 23800 | 10600 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1B | 29.4B |
| IPO Year | N/A | N/A |
| Metric | NTRS | RMD |
|---|---|---|
| Price | $164.85 | $192.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 10 |
| Target Price | $163.55 | ★ $292.56 |
| AVG Volume (30 Days) | 815.6K | ★ 1.4M |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.94% | 1.13% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.40 | $10.60 |
| Revenue Next Year | $4.13 | $7.41 |
| P/E Ratio | ★ $16.88 | $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $104.99 | $198.61 |
| 52 Week High | $173.19 | $293.81 |
| Indicator | NTRS | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 54.36 | 27.83 |
| Support Level | $158.98 | N/A |
| Resistance Level | $173.19 | $260.21 |
| Average True Range (ATR) | 2.99 | 5.34 |
| MACD | -0.27 | 0.01 |
| Stochastic Oscillator | 54.26 | 4.76 |
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2025, Northern Trust had assets under custody or administration of $18.7 trillion and assets under management of $1.8 trillion.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.